Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Net Interest Income

Last Annual Value

170.26K

3-Year CAGR

51%

5-Year CAGR

34%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Net Interest Income

NTRB · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
170.26K
N/AN/AN/A 
6.05M
12.6%227.7%N/A
1.40M
-35.3%3.1%N/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
5.59M
-18.7%64.3%N/A
6.48M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
5.74M
-16.8%N/AN/A
244.39K
-20.9%81.2%N/A
-293.00K
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-1.23M
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
2.04M
-34.1%145.1%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
1.04M
-30.3%73.6%N/A
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15